3/17
05:14 pm
prld
Prelude Therapeutics Announces Acceptance of Preclinical Abstract for PRT13722, a First-in-Class Oral KAT6A Selective Degrader at the 2026 AACR Annual Meeting [Yahoo! Finance]
Medium
Report
Prelude Therapeutics Announces Acceptance of Preclinical Abstract for PRT13722, a First-in-Class Oral KAT6A Selective Degrader at the 2026 AACR Annual Meeting [Yahoo! Finance]
3/17
04:31 pm
prld
Prelude Therapeutics Announces Acceptance of Preclinical Abstract for PRT13722, a First-in-Class Oral KAT6A Selective Degrader at the 2026 AACR Annual Meeting
Medium
Report
Prelude Therapeutics Announces Acceptance of Preclinical Abstract for PRT13722, a First-in-Class Oral KAT6A Selective Degrader at the 2026 AACR Annual Meeting
3/11
08:03 am
prld
Prelude Therapeutics (PRLD) had its price target raised by Citizens Jmp from $3.00 to $6.00. They now have a "market outperform" rating on the stock.
Medium
Report
Prelude Therapeutics (PRLD) had its price target raised by Citizens Jmp from $3.00 to $6.00. They now have a "market outperform" rating on the stock.
3/10
07:37 am
prld
Prelude Therapeutics Reports Full Year 2025 Financial Results and Provides Program Outlook for 2026 [Yahoo! Finance]
High
Report
Prelude Therapeutics Reports Full Year 2025 Financial Results and Provides Program Outlook for 2026 [Yahoo! Finance]
3/10
07:01 am
prld
Prelude Therapeutics Reports Full Year 2025 Financial Results and Provides Program Outlook for 2026
High
Report
Prelude Therapeutics Reports Full Year 2025 Financial Results and Provides Program Outlook for 2026
2/3
09:14 am
prld
Prelude Therapeutics Receives FDA Clearance of Investigational New Drug Application (IND) for PRT12396, a Mutant-selective JAK2V617F Inhibitor [Yahoo! Finance]
High
Report
Prelude Therapeutics Receives FDA Clearance of Investigational New Drug Application (IND) for PRT12396, a Mutant-selective JAK2V617F Inhibitor [Yahoo! Finance]
2/3
09:00 am
prld
Prelude Therapeutics Receives FDA Clearance of Investigational New Drug Application (IND) for PRT12396, a Mutant-selective JAK2V617F Inhibitor
Low
Report
Prelude Therapeutics Receives FDA Clearance of Investigational New Drug Application (IND) for PRT12396, a Mutant-selective JAK2V617F Inhibitor
1/18
01:00 am
prld
Prelude Therapeutics (NASDAQ:PRLD) was downgraded by analysts at
Wall St
Low
Report
Prelude Therapeutics (NASDAQ:PRLD) was downgraded by analysts at
Wall St
1/10
01:07 am
prld
Prelude Therapeutics (NASDAQ:PRLD) was upgraded by analysts at
Wall Stre
High
Report
Prelude Therapeutics (NASDAQ:PRLD) was upgraded by analysts at
Wall Stre
12/29
06:48 am
prld
Prelude Therapeutics Incorporated's (NASDAQ:PRLD) Path To Profitability [Yahoo! Finance]
High
Report
Prelude Therapeutics Incorporated's (NASDAQ:PRLD) Path To Profitability [Yahoo! Finance]